Selective therapies are needed. Report about reation to B-cells treatment.
Selective therapies are needed. Report about reation to B-cells treatment.
https://n.neurology.org/content/92/15_S ... 1.abstract
Immunological phenotyping identifies a subgroup of MS patients experiencing a proinflammatory immune cell activation upon therapeutic B cell removal
Abstract
Objective: To study how anti-CD20 treatment of multiple sclerosis (MS) patients affects activation and cytokine production of myeloid antigen-presenting cells (APC) and T cells and whether a pre-existing regulatory B cell phenotype correlates with the extent of immune cell activation upon therapeutic B cell removal.
Background: In MS, B cell-depleting anti-CD20 antibodies efficiently reduce relapses and central nervous system lesion formation by abrogating APC function and pro-inflammatory cytokine secretion of B cells. However, B cells are moreover capable of regulating immune cells via anti-inflammatory cytokines, e.g. interleukin-10, a property which may be concomitantly eradicated by anti-CD20.
Design/Methods: To study the influence of B cells on other immune cells, we co-cultured murine macrophages, B and T cells in various settings. To investigate the effects of anti-CD20, we collected peripheral blood mononuclear cells of MS patients before and after treatment initiation and assessed phenotype and cytokine signature of B, T and myeloid cells by flow cytometry and ELISPOT.
Results: We identified a triangle of B, T and myeloid cells, in which B cell-derived interleukin-6 enhanced myeloid APC and T cell activation. Conversely, B cell-produced interleukin-10 regulated the APC-T cell axis in an anti-inflammatory manner. Reflecting these interactions, we identified distinct subgroups of MS patients with a pro-versus anti-inflammatory differentiation of monocytes and T cells after therapeutic removal of B cells.
Conclusions: The B cell-generated cytokine milieu is capable of shaping the activity of other immune cells. While in most MS patients, anti-CD20 treatment resulted in a desirable immunological outcome, others displayed an accentuated immune cell activation. We hypothesize that the latter situation reflects the loss of pre-existing B cell regulation, which we are currently evaluating. In context with clinical data, these investigations aim to generate immunological biomarkers to identify individual patients in whom B cells should not be unselectively eradicated.
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 314 Views
-
Last post by NHE
Sun Sep 20, 2020 2:53 pm
-
-
Extrinsic defect in B cells differentiation through alteration of T FH cells
by frodo » Thu Jun 27, 2019 12:58 am » in MS Etiology and Pathogenesis - 0 Replies
- 670 Views
-
Last post by frodo
Thu Jun 27, 2019 12:58 am
-
-
-
anti-CD20 works on B-cells but also on T-cells
by frodo » Wed Aug 19, 2020 4:56 am » in MS Etiology and Pathogenesis - 0 Replies
- 187 Views
-
Last post by frodo
Wed Aug 19, 2020 4:56 am
-
-
- 1 Replies
- 188 Views
-
Last post by jimmylegs
Fri May 01, 2020 6:58 am
-
-
Report against division of MS in clinical types
by frodo » Wed Apr 03, 2019 6:56 am » in MS Etiology and Pathogenesis - 0 Replies
- 552 Views
-
Last post by frodo
Wed Apr 03, 2019 6:56 am
-
-
-
passing REAL MS to mice. New report 2020. An IgG-driven kind of MS found.
by frodo » Wed Apr 22, 2020 12:41 am » in MS Etiology and Pathogenesis - 0 Replies
- 235 Views
-
Last post by frodo
Wed Apr 22, 2020 12:41 am
-
-
- 0 Replies
- 553 Views
-
Last post by frodo
Tue Jun 25, 2019 7:18 am
-
-
Age of cells populations in MS
by frodo » Wed Jun 19, 2019 4:01 am » in MS Etiology and Pathogenesis - 0 Replies
- 505 Views
-
Last post by frodo
Wed Jun 19, 2019 4:01 am
-
-
- 0 Replies
- 337 Views
-
Last post by Petr75
Sat Dec 12, 2020 11:13 am